Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Gyroscope Therapeutics, headquartered in Stevenage, UK, is merging with Ambler, Pennsylvania-based Orbit Biomedical. They will operate under the Gyroscope name and focus on gene therapies for diseases of the eye.
Heidelberg Pharma AG reported on the first three months of fiscal year 2019 (1 December 2018 - 28 February 2019) and the Group’s financial figures.
Pharming Group N.V. announces that the Notice to Convene for its Annual General Meeting of Shareholders has been uploaded on its website.
The shareholders in BioArctic AB, corporate identity number 556601-2679 are hereby summoned to the Annual General Meeting to be held on May 9, 2019, at 5 p.m., at Grant Thornton Sweden AB’s offices, Sveavägen 20, Stockholm, Sweden.
MorphoSys AG announced that it has published its agenda for the Company’s ordinary Annual General Meeting, which will take place on Wednesday, May 22, 2019.
Galapagos NV announced that its board of directors created 2,070,000 warrants under new warrant plans for the benefit of the employees, directors, and a consultant of the company and its subsidiaries.
Pharming has acquired its shareholding through the conversion of €2.5 million of existing credits and €1.6 million of new cash subscription for a total of €4.1 million in BioConnection shares, plus additional shares acquired from existing investors.
Bionovate Technologies, Corp. announced that during the last fiscal year’s reporting period, it acquired a patent from Ramot University in Tel Aviv, Israel as part of the company’s strategy to develop non-invasive cancer imaging and identification systems.
Aresus takes over Veregen® business including API stock and intends to invest in expanding Veregen® into indications and markets
A summary of IPOs from companies in the biotech and pharma world since April 1, 2019.